Emerging Pharmacotherapies for Neurodevelopmental Disorders

Department of Psychiatry and Behavioral Sciences, Nancy Pritzker Laboratory, Stanford University, Stanford, CA 94305-5485, USA.
Journal of developmental and behavioral pediatrics: JDBP (Impact Factor: 2.13). 09/2010; 31(7):564-81. DOI: 10.1097/DBP.0b013e3181ee3833
Source: PubMed


A growing and interdisciplinary translational neuroscience research effort for neurodevelopmental disorders (NDDs) is investigating the mechanisms of dysfunction and testing effective treatment strategies in animal models and, when possible, in the clinic. NDDs with a genetic basis have received particular attention. Transgenic animals that mimic genetic insults responsible for disease in man have provided insight about mechanisms of dysfunction, and, surprisingly, have shown that cognitive deficits can be addressed in adult animals. This review will present recent translational research based on animal models of genetic NDDs, as well as pharmacotherapeutic strategies under development to address deficits of brain function for Down syndrome, fragile X syndrome, Rett syndrome, neurofibromatosis-1, tuberous sclerosis, and autism. Although these disorders vary in underlying causes and clinical presentation, common pathways and mechanisms for dysfunction have been observed. These include abnormal gene dosage, imbalance among neurotransmitter systems, and deficits in the development, maintenance and plasticity of neuronal circuits. NDDs affect multiple brain systems and behaviors that may be amenable to drug therapies that target distinct deficits. A primary goal of translational research is to replace symptomatic and supportive drug therapies with pharmacotherapies based on a principled understanding of the causes of dysfunction. Based on this principle, several recently developed therapeutic strategies offer clear promise for clinical development in man.

Full-text preview

Available from:
  • Source
    • "Gene therapy for the neurofibromin 1 gene represents the ultimate solution to prevent the cluster of maladies that are enabled by the mutation.[2425] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Plexiform neurofibromas (PNFs) are one of the most common and debilitating complications of neurofibromatosis type I (NF-I). They account for substantial morbidity, disfigurement, functional impairment and are life threatening. PNFs can also be subjected to transformation into malignant peripheral nerve sheath tumor (MPNST). This complication is refractory to treat due to paucity of effective therapies for malignant soft tissue sarcomas in general and also the delay in diagnosis from a preexisting tumor. We report a case of PNF of face involving oral cavity with literature review.
    Journal of Oral and Maxillofacial Pathology 04/2014; 18(1):114-7. DOI:10.4103/0973-029X.131932
  • Source
    • "Reduction of inhibition in the visual system, for example, can restore a juvenile state of plasticity in the adult rodent brain (Espinosa and Stryker, 2012; Maya Vetencourt et al., 2008). Many genetic disorders with cognitive deficits, such as autism and Down syndrome, are also associated with excessive inhibition (Ramamoorthi and Lin, 2011; Wetmore and Garner, 2010). In the case of Down syndrome, reducing inhibition in a genetic model was found to improve cognitive function (Fernandez et al., 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Much progress has been made in understanding how behavioral experience and neural activity can modify the structure and function of neural circuits during development and in the adult brain. Studies of physiological and molecular mechanisms underlying activity-dependent plasticity in animal models have suggested potential therapeutic approaches for a wide range of brain disorders in humans. Physiological and electrical stimulations as well as plasticity-modifying molecular agents may facilitate functional recovery by selectively enhancing existing neural circuits or promoting the formation of new functional circuits. Here, we review the advances in basic studies of neural plasticity mechanisms in developing and adult nervous systems and current clinical treatments that harness neural plasticity, and we offer perspectives on future development of plasticity-based therapy.
    Neuron 10/2013; 80(3):729-41. DOI:10.1016/j.neuron.2013.10.028 · 15.05 Impact Factor
  • Source
    • "Targeted pharmacologic treatments for DS are also being developed, including a drug that acts as a GABA receptor antagonist (Hoffmann-La Roche, Basel, Switzerland) which may improve learning and memory in individuals with DS [17]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Down syndrome is the most common identifiable genetic cause of intellectual disability, with a unique physical gestalt that makes diagnosis possible during the newborn period. However, the physical characteristics of Fragile X syndrome are fairly subtle, resulting in the first clinical suspicion often arising from delayed developmental milestones. In addition, maladaptive behavior and autistic-like tendencies, such as hand flapping, poor eye contact, and hand biting, may be noted in Fragile X syndrome but are not as commonly observed in Down syndrome. Recognition of a potential secondary diagnosis, such as Fragile X syndrome, in individuals with Down syndrome is critical because there have been advances in targeted pharmacologic treatments for both conditions. Thus, an accurate diagnosis has implications in improving the individual's quality of life.
    09/2013; 2013:504695. DOI:10.1155/2013/504695
Show more